Edit Entry

Todd W Miller, PhD

Title(s):
Associate Professor of Molecular and Systems Biology

Additional Titles/Positions/Affiliations:
Scientific Director, Comprehensive Breast Program, Norris Cotton Cancer Center
Co-Director, Molecular Tumor Board, Norris Cotton Cancer Center

Department(s):
Molecular and Systems Biology

Education:
University of Connecticut (Storrs, CT), B.S., 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004

Programs:
Program in Experimental and Molecular Medicine

Websites:
Lab website:
https://geiselmed.dartmouth.edu/miller/

Publications:
http://www.ncbi.nlm.nih.gov/sites/myncbi/todd.miller.1/bibliography/42064063/public/?sort=date&direction=descending

Contact Information:

1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756

Office: Rubin 604
Phone: 603-653-9284
Fax: 603-653-9952
Email: Todd.W.Miller@Dartmouth.edu


Professional Interests:

Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development

Rotations and Thesis Projects:

1) Identify therapeutic drug targets in dormant breast cancer cells.
2) Develop novel, organ-specific models of metastatic breast cancer; determine underlying differences in gene/protein expression and therapeutic sensitivity between tumors in different organs.

Grant Information:

R01 CA200994 (PI: Miller) 04/01/2017 – 03/31/2022
NIH/NCI
A precision medicine basis for estrogen therapy for advanced breast cancer.

R01 CA211869 (PI: Miller)
09/04/2017 – 08/31/2022
NIH/NCI
A precision medicine basis for Pl3K inhibition in ER+ breast cancer.

Pilot Project Grant (PI: Miller) 08/01/2014 – no end
Norris Cotton Cancer Center Early-Phase Trials Program
Alternating estradiol and anti-estrogen therapies to prevent disease progression in advanced ER+/HER2- breast cancer.

Investigator-initiated Phase I clinical study (PI: Schwartz)
Takeda Pharmaceuticals 10/01/2015 – no end
Phase 1 study of combination of MLN9708 and Fulvestrant in patients with advanced ER+ breast cancer.

Courses Taught:

PEMM 102- Scientific Basis of Disease II
PEMM 126- Cancer Biology
PEMM 132- Clinical Management of Cancer

Biography:

Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth in 2012.

Mentoring Information:

2012-2014 Lloye Dillon, Ph.D., Postdoctoral Fellow (Current Position: Senior Scientist, Research & Development, OncoTAb, Inc., Charlotte, NC)
2012-2018 Wei Yang, M.S., PhD Student (Current position: Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center)
2013-2018 Sarah Hosford, PhD Student (Current position: Scientist in In Vivo Pharmacology at Cobalt Biomedicine)
2014-2018 Kevin Shee, MD/PhD student (Current position: medical student at Geisel)
2015-present Riley Hampsch, PhD student
2016-present Nicole Traphagen, PhD student
2017-present Jason Wells, PhD student
2017-present Bianca Romo, PhD student
2018-present Jackie Griffin, PhD, Postdoctoral Fellow


Selected Publications:

 

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Hosford SR, Shee K, Wells JD, Traphagen NA, Fields JL, Hampsch RA, Kettenbach AN, Demidenko E, Miller TW
Mol Oncol. 2019 Jun 10; doi: 10.1002/1878-0261.12528. Epub 2019 Jun 10.
PMID: 31180176

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y, Wang Y, Salas LA, Miller TW, Mark K, Marotti JD, Kettenbach AN, Cheng C, Christensen BC
Breast Cancer Res. 2019 Jan 25;21(1):14. doi: 10.1186/s13058-018-1090-z. Epub 2019 Jan 25.
PMID: 30683142

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.
Shee K, Muller KE, Marotti J, Miller TW, Wells WA, Tsongalis GJ
Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29.
PMID: 30385093

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW
FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.
PMID: 30161001

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW
Oncotarget. 2018 Feb 6;9(10):8810-8822. doi: 10.18632/oncotarget.24256. Epub 2018 Jan 15.
PMID: 29507656

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.
Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Pare L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.
PMID: 29476008

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.
Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW
J Exp Med. 2018 Mar 5;215(3):895-910. doi: 10.1084/jem.20171818. Epub 2018 Feb 7.
PMID: 29436393

Trailblazing Precision Oncology for Rare Tumor Subtypes.
Shee K, Miller TW
Oncologist. 2018 Feb;23(2):143-144. doi: 10.1634/theoncologist.2017-0494. Epub 2017 Nov 20.
PMID: 29158369

Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW
FASEB J. 2018 Mar;32(3):1222-1235. doi: 10.1096/fj.201700477R. Epub 2018 Jan 3.
PMID: 29127189

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
Marotti JD, Muller KE, Tafe LJ, Demidenko E, Miller TW
Int J Breast Cancer. 2017;2017:4537532. doi: 10.1155/2017/4537532. Epub 2017 Jun 15.
PMID: 28698809

View more publications on PubMed